Flow Cytometry: Principles and Methods

Published on :

This four day program is ideal for those who are looking for an in-depth, hands-on introduction to Flow Cytometry. The instructors will focus on a broad spectrum of flow cytometric [….]

Antibody Validation and Characterization

Published on :

Team taught by active researchers, this two day program is ideal for basic research and translational biology scientists who work with antibodies on a regular basis. This program which focuses [….]

Multiplex Immunofluorescence in Immune Oncology, Workshop & Symposium

Published on :

This four day program is divided into a two-day symposium with lectures presented by world class scientists in the field of immuno-oncology and with representation by all the main multiplex [….]

Flow Cytometry: Principles, Methods and Applications

Published on :

This four day program is ideal for those who are looking for an in-depth, hands-on introduction to Flow Cytometry. Developed and taught by active researchers, this workshop will focus on [….]

Miltenyi Biotec promotes Markus Weiss to Executive Vice President

Published on :

Markus Weiss, who in this role is responsible for supporting the North American Business Units and Divisions has 18 years of experience in operationalizing strategy, preserving and growing value, scaling culture as well as business transformations. He is experienced in divisional, regional and country level leadership roles in technology, life science, manufacturing, construction and financial services.

Cerecor Rebrands to Avalo Therapeutics

Published on :

Cerecor Rebrands to Avalo Therapeutics. Eighteen months after completing its merger with Aevi Genomic Medicine, Cerecor is rebranding to Avalo Therapeutics. The rebranding to Avalo reflects the company’s aims to focus on three core indications, on immunology, immuno-oncology, and rare genetic diseases.

Myeloid Therapeutics and MaxCyte Enter Clinical and Commercial Licensing Agreement to Advance Myeloid’s Cell Therapy Programs

Published on :

Patented high-performance cell-engineering platform to biopharmaceutical partners engaged in drug discovery and development, biomanufacturing and cell therapy, including gene editing and immuno-oncology.